Quarterly ResultMay 14, 2026, 04:23 PM
DMII Q1 Net Income $4.34M; Trust Account $509.37M
AI Summary
Drugs Made In America Acquisition II Corp. reported a net income of $4,337,820 for the three months ended March 31, 2026, a significant improvement from a net loss of $(59,327) in the prior year period, primarily due to interest earned on its Trust Account. The company's cash and investments held in the Trust Account increased to $509,373,650. Despite these financial improvements, management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern, citing its dependence on completing a business combination within a prescribed period.
Key Highlights
- Net income for Q1 2026 was $4,337,820, compared to a net loss of $(59,327) in Q1 2025.
- Cash and investments in Trust Account totaled $509,373,650 as of March 31, 2026.
- Total assets were $509,725,411 as of March 31, 2026.
- Total liabilities increased to $18,166,285 as of March 31, 2026.
- Interest earned on cash and investments in Trust Account was $4,439,850 for Q1 2026.
- The company reported a working capital deficit of $314,524 as of March 31, 2026.
- Promissory notes amounted to $450,000 as of March 31, 2026.
- A full reserve of $782,113 was established for amounts due from the Sponsor.